Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Page 1
Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes.
Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT. Zile MR, et al. Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3232. Online ahead of print. Eur J Heart Fail. 2024. PMID: 38606555
We tested the hypothesis that treatment with BAT significantly reduces cardiovascular mortality and heart failure morbidity and provides long-term safety and sustainable symptomatic improvement. METHODS AND RESULTS: BeAT-HF was a prospective, multicentre, randomized, two-a …
We tested the hypothesis that treatment with BAT significantly reduces cardiovascular mortality and heart failure morbidity and provides lon …
Implantable Hemodynamic Monitors Improve Survival in Patients With Heart Failure and Reduced Ejection Fraction.
Lindenfeld J, Costanzo MR, Zile MR, Ducharme A, Troughton R, Maisel A, Mehra MR, Paul S, Sears SF, Smart F, Johnson N, Henderson J, Adamson PB, Desai AS, Abraham WT; GUIDE-HF, CHAMPION, and LAPTOP-HF Investigators. Lindenfeld J, et al. Among authors: zile mr. J Am Coll Cardiol. 2024 Feb 13;83(6):682-694. doi: 10.1016/j.jacc.2023.11.030. J Am Coll Cardiol. 2024. PMID: 38325994
Prior meta-analyses assessing mortality have been limited in construct because of an absence of patient-level data, short-term follow-up duration, and evaluation across the combined spectrum of ejection fractions. ...
Prior meta-analyses assessing mortality have been limited in construct because of an absence of patient-level data, short-term follow …
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
Chatur S, Claggett BL, McCausland FR, Rouleau J, Zile MR, Packer M, Pfeffer MA, Lefkowitz M, McMurray JJV, Solomon SD, Vaduganathan M. Chatur S, et al. Among authors: zile mr. J Am Coll Cardiol. 2023 Apr 18;81(15):1443-1455. doi: 10.1016/j.jacc.2023.02.009. Epub 2023 Feb 20. J Am Coll Cardiol. 2023. PMID: 36812948 Free article.
Whether such changes portend adverse outcomes or influence long-term treatment benefits with sacubitril/valsartan continuation is unknown. ...CONCLUSIONS: Moderate eGFR decline when transitioning from RASi to sacubitril/valsartan is not consistently associated with adverse …
Whether such changes portend adverse outcomes or influence long-term treatment benefits with sacubitril/valsartan continuation is unk …
Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States.
Bisognano J, Schneider JE, Davies S, Ohsfeldt RL, Galle E, Stojanovic I, Deering TF, Lindenfeld J, Zile MR. Bisognano J, et al. Among authors: zile mr. BMC Cardiovasc Disord. 2021 Mar 26;21(1):155. doi: 10.1186/s12872-021-01958-y. BMC Cardiovasc Disord. 2021. PMID: 33771104 Free PMC article.
As additional BeAT-HF trial data become available, the model can be updated to show longer term effects....
As additional BeAT-HF trial data become available, the model can be updated to show longer term effects....
Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices.
Tomashitis B, Baicu CF, Butschek RA, Jackson GR, Winterfield J, Tedford RJ, Zile MR, Gold MR, Houston BA. Tomashitis B, et al. Among authors: zile mr. J Am Heart Assoc. 2021 Mar 16;10(6):e018127. doi: 10.1161/JAHA.120.018127. Epub 2021 Mar 5. J Am Heart Assoc. 2021. PMID: 33663225 Free PMC article. Clinical Trial.
We aimed to quantify the hemodynamic effects of different ventricular pacing configurations in patients with LVADs, focusing on short-term changes in load-independent right ventricular (RV) contractility. ...
We aimed to quantify the hemodynamic effects of different ventricular pacing configurations in patients with LVADs, focusing on short-ter …
Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion.
Faselis C, Lam PH, Patel S, Arundel C, Filippatos G, Deedwania P, Zile MR, Wopperer S, Nguyen T, Allman RM, Fonarow GC, Ahmed A. Faselis C, et al. Among authors: zile mr. Am J Med. 2021 Jun;134(6):797-804. doi: 10.1016/j.amjmed.2020.11.019. Epub 2021 Jan 28. Am J Med. 2021. PMID: 33359271
CONCLUSIONS: The association between a discharge loop diuretic prescription and long-term clinical outcomes in hospitalized patients with heart failure is modified by admission congestion with worse, neutral, and better outcomes in patients with no, mild-to-moderate, and s …
CONCLUSIONS: The association between a discharge loop diuretic prescription and long-term clinical outcomes in hospitalized patients …
Prediction of heart failure hospitalizations based on the direct measurement of intrathoracic impedance.
Zile MR, Sharma V, Baicu CF, Koehler J, Tang AS. Zile MR, et al. ESC Heart Fail. 2020 Oct;7(5):3040-3048. doi: 10.1002/ehf2.12930. Epub 2020 Aug 13. ESC Heart Fail. 2020. PMID: 32790059 Free PMC article.
AIMS: OptiVol fluid index was developed as a transthoracic impedance-based indicator of short-term risk for heart failure hospitalization (HFH). OptiVol is calculated as the accumulating difference between daily impedance (measured impedance) and long-term average i …
AIMS: OptiVol fluid index was developed as a transthoracic impedance-based indicator of short-term risk for heart failure hospitaliza …
Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure.
Faselis C, Arundel C, Patel S, Lam PH, Gottlieb SS, Zile MR, Deedwania P, Filippatos G, Sheriff HM, Zeng Q, Morgan CJ, Wopperer S, Nguyen T, Allman RM, Fonarow GC, Ahmed A. Faselis C, et al. Among authors: zile mr. J Am Coll Cardiol. 2020 Aug 11;76(6):669-679. doi: 10.1016/j.jacc.2020.06.022. J Am Coll Cardiol. 2020. PMID: 32762901 Free PMC article.
CONCLUSIONS: Hospitalized older patients not taking diuretics prior to hospitalization for HF decompensation who received a discharge prescription for loop diuretics had significantly better 30-day clinical outcomes than those not discharged on loop diuretics. These findings prov …
CONCLUSIONS: Hospitalized older patients not taking diuretics prior to hospitalization for HF decompensation who received a discharge prescr …
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J Jr, Mittleman RS, Profy AT, Seferovic JP, Reasner D, Konstam MA. Udelson JE, et al. Among authors: zile mr. Am Heart J. 2020 Apr;222:183-190. doi: 10.1016/j.ahj.2020.01.009. Epub 2020 Jan 21. Am Heart J. 2020. PMID: 32105984 Clinical Trial.
CONCLUSIONS: The CAPACITY HFpEF trial will provide data on short-term safety and efficacy of praliciguat on peak exercise capacity, as well as multiple secondary end points of submaximal functional capacity, patient-reported outcomes, and biomarkers....
CONCLUSIONS: The CAPACITY HFpEF trial will provide data on short-term safety and efficacy of praliciguat on peak exercise capacity, a …
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK, Claggett BL, Solomon SD, McMurray JJV, Packer M, Zile MR, Desai AS, Rouleau JL, Swedberg K, Fonarow GC. Srivastava PK, et al. Among authors: zile mr. JAMA Cardiol. 2018 Dec 1;3(12):1226-1231. doi: 10.1001/jamacardio.2018.3957. JAMA Cardiol. 2018. PMID: 30484837 Free PMC article. Clinical Trial.
IMPORTANCE: The addition of receptor-neprilysin inhibition to standard therapy, including a renin-angiotensin system blocker, has been demonstrated to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF) compared with standard therapy alone. The …
IMPORTANCE: The addition of receptor-neprilysin inhibition to standard therapy, including a renin-angiotensin system blocker, has been demon …
24 results